4//SEC Filing
Harwin Peter Evan 4
Accession 0001104659-25-097921
CIK 0001798749other
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 4:15 PM ET
Size
16.3 KB
Accession
0001104659-25-097921
Insider Transaction Report
Form 4
Fairmount Funds Management LLC
Director10% Owner
Transactions
- Award
Common Stock
2025-10-06$9.14/sh+1,333,126$12,184,772→ 1,897,677 total(indirect: By Fairmount Healthcare Fund II L.P.) - Award
Pre-Funded Warrant (Right to Buy)
2025-10-06$9.14/sh+855,047$7,815,044→ 855,047 total(indirect: By Fairmount Healthcare Fund II L.P.)Exercise: $0.00→ Common Stock (855,047 underlying)
Holdings
- 2,655,817(indirect: By Fairmount Healthcare Co-Invest IV L.P.)
Common Stock
Footnotes (3)
- [F1]The shares of Common Stock and Pre-Funded Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.
- [F2]Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest IV L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F3]The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.
Documents
Issuer
Jade Biosciences, Inc.
CIK 0001798749
Entity typeother
Related Parties
1- filerCIK 0001663607
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 4:15 PM ET
- Size
- 16.3 KB